Document is current
Any future updates will be listed below
-
Authors
Rutter-Locher, Zoe
Kirkham, Bruce W.
Bannister, Kirsty https://orcid.org/0000-0002-3043-3574
Bennett, David L. https://orcid.org/0000-0002-7996-2696
Buckley, Christopher D. https://orcid.org/0000-0001-6924-6402
Taams, Leonie S. https://orcid.org/0000-0002-9337-7194
Denk, Franziska https://orcid.org/0000-0003-4883-4234
- License Information
-
More Information
Article History
Accepted: 5 August 2024
First Online: 6 September 2024
Competing interests
: D.L.B. has received research grant funding from Eli Lilly and AstraZeneca. B.W.K. has been an adviser or speaker for AbbVie, Eli-Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB. F.D. receives funding from Ono Pharmaceuticals, is a Scientific Advisor for Cellectricon and is consulting for GSK. L.S.T. has received research funding, speaker or consultancy fees from Sanofi, CESAS Medical, UCB, GSK and AbbVie. C.D.B. has received research grant funding from Janssen, Roche and is an adviser for GSK and AbbVie. He is a founder of Mestag Therapeutics. None of the other authors declares any competing interests relevant to this Review.
